PLCD3

Across TCGA pan-cancer cohorts, PLCD3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLCD3 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PLCD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLCD3 expression acts as an unfavorable survival marker.

STAD, PAAD, and SCLC are the cancer types where PLCD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	30	view →
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
SCLC	OS	Median	All	0.178	0.714	<.001	18	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.114	0.662	<.001	5	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLCD3–STAD (OS)

Open the STAD breakdown →